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Luciferase and Luciferin Co-immobilized Mesoporous Silica Nanoparticle
Materials for Intracellular Biocatalysis
Abstract
We report a gold nanoparticle (AuNP)-capped mesoporous silica nanoparticle (Au-MSN) platform for
intracellular codelivery of an enzyme and a substrate with retention of bioactivity. As a proof-of-concept
demonstration, Au-MSNs are shown to release luciferin from the interior pores of MSN upon AuNP
uncapping in response to disulfide-reducing antioxidants and codeliver bioactive luciferase from the
PEGylated exterior surface of Au-MSN to Hela cells. The effectiveness of luciferase-catalyzed luciferin
oxidation and luminescence emission in the presence of intracellular ATP was measured by a luminometer.
Overall, the chemical tailorability of the Au-MSN platform to retain enzyme bioactivity, the ability to
codeliver enzyme and substrate, and the potential for imaging tumor growth and metastasis afforded by
intracellular ATP- and glutathione-dependent bioluminescence make this platform appealing for intracellular
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ABSTRACT: We report a gold nanoparticle (AuNP)-
capped mesoporous silica nanoparticle (Au-MSN) platform
for intracellular codelivery of an enzyme and a substrate with
retention of bioactivity. As a proof-of-concept demonstration,
Au-MSNs are shown to release luciferin from the interior
pores of MSN upon AuNP uncapping in response to
disulﬁde-reducing antioxidants and codeliver bioactive lucif-
erase from the PEGylated exterior surface of Au-MSN to
Hela cells. The eﬀectiveness of luciferase-catalyzed lucif-
erin oxidation and luminescence emission in the presence of
intracellular ATP was measured by a luminometer. Overall,
the chemical tailorability of the Au-MSN platform to retain
enzyme bioactivity, the ability to codeliver enzyme and
substrate, and the potential for imaging tumor growth and
metastasis aﬀorded by intracellular ATP- and glutathione-
dependent bioluminescence make this platform appealing
for intracellular controlled catalysis and tumor imaging.
Intracellular delivery and controlled release of multiple biogenicmolecules, such as genes, enzymes, proteins, and other mol-
ecules of pharmaceutical interest,15 provides a powerful tool for
therapeutics and fundamental studies of biological processes
such as enzyme-catalyzed reactions. While intracellular enzyme
delivery has been studied using nanocarriers,24 the codelivery of
enzyme and substrate for enzymatic reactions mediated by
intracellular factors has not been reported to date. Modulation
of enzymatic reactions by cellular factors provides a potent means
to gain information about cellular processes such as signal trans-
duction, DNA replication, andmetabolism. These cellular factors
can be considered as biological markers and therapeutic targets
for disease diagnosis and treatment.68 For example, a key
metabolite involved in maintaining a reduced intracellular redox
milieu is the tripeptide glutathione (GSH).9 GSH has long been
suggested to be part of signaling cascades transuding environ-
mental signals to the nucleus, and its elevated concentration in
many types of tumors is often associated with an increased re-
sistance to chemo- and radiotherapy.8 Likewise, as biological
energy, adenosine triphosphate (ATP) is involved in a multitude
of important intracellular physiological processes, such as protein
metabolism and cell apoptosis, the level of which is a measure of
tumor cell viability and growth.6 Therefore, intracellular code-
livery of enzymes and substrates for cellular factor (e.g., GSH and
ATP)-mediated enzymatic reactions would not only aﬀord novel
biocatalysis inside live cells but also ﬁnd application in monitor-
ing of tumor growth and metastasis. Two major challenges,
however, are (1) the design of nanomaterials for intracellular
controlled release of multiple biogenic species with preserved
bioactivity and (2) the development of methods for imaging and
quantiﬁcation of cellular-factor-mediated catalytic reactions.
Mesoporous silica nanoparticles (MSNs) were recently de-
monstrated to be excellent candidates as vehicles for codelivery
applications10,11 as a result of the coexistence of both interior
pore and exterior particle surfaces for loading various guest mole-
cules. This unique feature provides the possibility of using MSN
for controlled release and codelivery of enzymes and substrates
for intracellular enzymatic reactions. With respect to the chal-
lenge of imaging and quantiﬁcation, most studies on nanoparti-
cle-based tumor imaging have focused on their cellular uptake
and have relied heavily on ﬂuorescence readout, which cannot
provide biologically relevant information on cellular processes.
Bioluminescence has gained favor in the past decade as an
attractive approach for tumor imaging.1217 This technique is
based on light emission by the luciferase-catalyzed oxidation of
the luciferin substrate, which occurs in an ATP-dependent
manner.18,19 A vast number of experiments have been carried out to
examine tumor growth and the eﬀect of therapeutics using tumor
cell lines that have been genetically engineered to produce
luciferase.1217 However, the detection of photons is dependent
on the circulatory half-life of the injected luciferin substrate and
its perfusion into the tumor.20 The fast elimination of luciferin
from circulation makes utilizing it in many clinical applications
challenging.20 Both the sophisticated gene engineering and the
short circulatory half-life of luciferin call for novel nanomaterials
for intracellular codelivery of luciferase and luciferin, which
would oﬀer the additional advantage of improved tumor uptake
via the enhanced permeability and retention (EPR) eﬀect.21
Herein we report the development of a gold nanoparticle
(AuNP)-capped MSN (Au-MSN) system and our investigations
of the intracellular codelivery of luciferase and luciferin as a
model enzymesubstrate pair. As depicted in Figure 1, luciferin
is loaded in the mesopores of the MSNs and encapsulated with
disulﬁde-linked AuNPs that physically block the luciferin from
leaching out. Luciferase is physisorbed on the PEGylated external
surface of the Au-MSNs through electrostatic interactions, as
previously demonstrated.22 Luciferin molecules trapped inside
the pores are released upon uncapping by intracellular disulﬁde-
reducing antioxidants such asGSHor cysteine or the introduction
of dithiothreitol (DTT).23 The released luciferin is in turn con-
verted by the codelivered luciferase to oxyluciferin in the
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presence of intracellular ATP and cofactor Mg2+, along with the
release of energy in the form of photons that can be measured
with a luminometer.
We ﬁrst synthesized a 3-(propyldisulfanyl)ethylamine (0.9mmol
g1)-functionalized mesoporous silica nanosphere (linker-MSN)
material using our previously reported method.23,24 As described
in the Supporting Information (SI), the material was PEGylated
by grafting 2-[methoxy(polyethylenoxy)propyl]trimethoxysilane to
yield the PEGylated (0.1 mmol g1) linker-MSNwith an average
particle diameter of 160 nm and an MCM-41-type channel-like
mesoporous structure (BJH pore diameter = 2.5 nm) (Figure 2a).
We then functionalized the surface of the AuNPs with a
carboxylic acid-terminated poly(ethylene glycol) (PEG) linker
(Figure 1) through exchange of 1-propanethiol-protected AuNPs25
with PEG-functionalized thiol ligands in dichloromethane (see
the SI). The PEG-functionalized AuNPs (PEG-AuNPs) were
negatively charged (ζ potential = 39.6 mV) in PBS (pH 7.4)
with an average particle diameter of 3 nm, as determined by
transmission electron microscopy (TEM) (Figure S3b in the SI).
Before the enzymesubstrate Au-MSN system was con-
structed, the inﬂuence of MSNs and AuNPs on the enzymatic
activity of luciferase was analyzed by means of a luciferase activity
assay.26,27 As shown in Figure S4, the luciferase activity was
depressed dramatically upon incubation with linker-MSNs and
1-propanethiol-stabilized AuNPs, with activities of ∼20 and
<15%, respectively, after only 1 h incubation. However, nearly
75 and ∼63% of the luciferase activity was observed after 3 h of
contact with PEGylated linker-MSNs and PEG-AuNPs, respec-
tively. The enzymatic activity of luciferase was also found to be
dependent on the incubation time. A slight decrease in luciferase
activity was found when the incubation time was increased from
3 to 24 h, in which nearly 60 and ∼62% of the activity were
observed for PEGylated linker-MSNs and PEG-AuNPs, respec-
tively. These data demonstrate that surface PEGylation plays a
crucial role in improving the biocompatibility of MSNs and
AuNPs for the retention of enzyme bioactivity, which is con-
sistent with other literature reports.22,28
Having demonstrated the surface biocompatibility of the materi-
als, we utilized the Au-MSN platform to adsorb and encapsulate
the enzymatic substrate, luciferin. To do so, the mesopores of
PEGylated linker-MSN (25 mg) were loaded with luciferin
(33 μM) in PBS buﬀer (pH 7.4) and then capped with PEG-
AuNPs (25 mg) through amide bond formation between the
carboxylic acid groups of PEG-AuNPs and the amino groups of
PEGylated linker-MSNs (Figure 1), giving rise to the desired
luciferin-loaded Au-MSNs (Figure 2b). The loading of luciferin
was determined to be 13.1 μmol g1 by ﬂuorescence emission
spectroscopy (see the SI).
TEM imaging provided visual evidence of the mesopore capping
with PEG-AuNPs. Figure 2 shows TEM images of PEGylated
linker-MSNs before and after capping with PEG-AuNPs. In the
case of the uncapped MSN (Figure 2a), the hexagonally packed
mesoporous channels are clearly visible. In contrast, the TEM
image of a luciferin-loaded Au-MSN (Figure 2b) shows dark spots
on theMSN surface that represent the attachment of AuNPs on the
MSN exterior surface.
To determine whether the release of luciferin from the luciferin-
loaded Au-MSNs could be induced by disulﬁde cleavage as
desired for intracellular controlled release, luciferin-loaded Au-
MSNs (1 mg mL1) were suspended in PBS buﬀer (pH 7.4) for
23 h before addition of 1 mM DTT. As shown in Figure 3a, the
Au-MSN drug delivery system exhibited less than 5.0% drug
release in PBS buﬀer over of the initial 23 h period. This result
suggests a good capping eﬃciency of the AuNPs for encapsulation
of the luciferin molecules against leaching. Addition of disulﬁde-
reducing DTT (1 mM) triggered the release of the mesopore-
entrapped luciferin. The rate of luciferin release slightly de-
creased over time until 100% of the total cumulative release
(1.44 μmol g1) was reached in 8 h. In addition, the controlled
release of luciferin mediated by the Au-MSN system would oﬀer
the advantage of improving the circulatory half-life of luciferin
Figure 1. Schematic representation of Au-MSNs for intracellular
codelivery of luciferase and luciferin.
Figure 2. TEM images of (a) PEGylated linker-MSNs and (b) a luciferin-
loaded Au-MSN. A high-magniﬁcation image of a luciferin-loaded Au-MSN
is shown in Figure S3d.
Figure 3. (a) Cumulative release of luciferin from a suspension of
luciferin-loaded Au-MSNs (1 mg mL1) after addition of 1 mMDTT at
23 h. (b) Resultant luminescence from the luciferaseluciferin Au-MSN
suspension (1 mg mL1) in the presence of ATP (80 μM) and Mg2+
(8 mM) after the addition of (blue) 0.1, (green) 0.5, (red) 1, and (black)
10 mM DTT at 60 min.
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and also promote tumor uptake via the EPR eﬀect, as required in
various in vitro and in vivo luminescence assays. In addition, the
disulﬁde linkage design renders the release of luciferin predomi-
nately inside the cells.9,23,24
The most advantageous feature of this Au-MSN platform is
the potential to deliver diﬀerent biogenic species simultaneously
in a controlled fashion. To construct the enzymesubstrate code-
livery system, luciferase was immobilized on the external surface
of Au-MSNs by incubating luciferin-loadedAu-MSNs (1mgmL1)
with luciferase (1 mg mL1) in PBS buﬀer (pH 7.4) for 2 h,
followed by centrifugation and freeze-drying. The loading of
luciferase was measured to be 29.7 μmol g1 by a luciferase
activity assay (see the SI). This system will henceforth be called
luciferaseluciferin Au-MSN. To examine the applicability of
this controlled-release codelivery system, the DTT-stimulated
luciferaseluciferin reaction was conducted in situ as described
in the SI. The luminescence intensity remained at background
level over a period of 60 min before the addition of disulﬁde-
bond reducing agents, suggesting a “zero premature release”
property of this system. After addition of DTT (1 mM), luciferin
was released and converted to oxyluciferin in a luciferase-catalyzed
light-emitting reaction. As shown in Figure 3b, the pattern of
luminescence as a function of time was similar for all DTT doses
(0.1, 0.5, 1, and 10 mM). The highest luminescence signal was
detected at t = 5 min and gradually decayed, reaching background
after∼180min. The observed luminescence strongly depended on
theDTT concentration. An increase in the luminescence signal was
observed with growing DTT dose up to 1 mM, suggesting a dose-
dependent controlled-release proﬁle. Importantly, when 10 mM
DTT was introduced to the system, the luminescence showed a
15% reduction in intensity relative to the signal triggered by 1 mM
DTT, which can be attributed to the denaturation of luciferase at
high DTT concentrations.29 Hence, the eﬀectiveness of the lucifer-
aseluciferin reaction on the Au-MSN platform depends on the
strength of the reducing environment to which it is exposed.
Prior to functional biological studies of the luciferaseluciferin
Au-MSNs, it was necessary to evaluate the cellular uptake and
cytotoxic eﬀects of the material. To do so, we ﬁrst assessed the
cellular uptake of ﬂuorescein isothiocyanate (FITC)-labeled
luciferaseluciferin Au-MSNs (denoted as luciferaseluciferin
FITC-Au-MSNs) by human cervical carcinoma (Hela) cells over
time. The cells were incubated in the presence of the NPs
(50 μg mL1) for increasing periods of time. The percentage of
cells internalizing luciferaseluciferin FITC-Au-MSNs was then
monitored by ﬂow cytometry using the trypan blue exclusion
method for quenching the ﬂuorescence of extracellular particles.30
As shown in Figure S5, the percent of FITC-positive cells in-
creased with time, reaching over 80% of total cellular uptake at
3 h of contact and a plateau in∼6 h. In view of the aforementioned
incubation time eﬀect on the luciferase activity (Figure S4), 3 h of
contact was selected for the following biological experiments. We
performed confocal ﬂuorescence microscopy (Figure 4ac) and
TEM (Figure 4df) analyses of Hela cells 3 h after treatment with
50 μg mL1 luciferaseluciferin FITC-Au-MSNs and luciferase
luciferin Au-MSNs, respectively. Indeed, the nanoparticles were
easily visible inside the cells, conﬁrming uptake of the materials.
Finally, the toxicity of the luciferaseluciferin Au-MSNs was
assessed by Guava ViaCount cytometry assay with Hela cells.
Following 24 h of treatment, we observed minimal toxicity
(>95% cell viability) at concentrations of the material as high
as 100 μg mL1 (Figure S6), consistent with the good biocom-
patibility of MSNs23,31 and AuNPs.32
To demonstrate that the enzymesubstrate Au-MSN system
can deliver both the enzyme luciferase and the substrate luciferin
for intracellular ATP- and redox-potential-mediated biocatalysis,
the luciferaseluciferin Au-MSNs (50 μg mL1) were inter-
nalized by Hela cells. After 3 h of incubation, the intracellular
luciferase-catalyzed luciferin conversion and light emission was
assessed by means of an intracellular luciferase activity assay (see
the SI). As shown in Figure 5a, a burst of luminescence was
observed immediately and slowly decayed over the next 30 min.
Neither untreated Hela cells nor cells treated with a solution
containing free luciferase and luciferin (10- and 15-fold relative to
the loading amounts, respectively) generated detectable lumi-
nescence, consistent with the low extracellular ATP level33,34 and
the membrane impermeability of luciferase.35 Therefore, the
observed luminescence can be attributed to the capability of
our Au-MSN system for intracellular codelivery of enzyme and
substrate. Furthermore, our model system provides a means of
further regulating the enzymatic reaction inside live cells. As a
ﬁrst demonstration of intracellular catalysis with tunability, the
enzymatic reaction eﬃciency was increased by enhancing the
Figure 4. (a) Fluorescence confocal micrographs of Hela cells (4 105
cells mL1) internalized with luciferaseluciferin FITC-Au-MSNs
(50 μg mL1, green) for 3 h. Cell nuclei were stained with DAPI (blue).
(b) Corresponding bright-ﬁeld image ofHela cells. (c) Fluorescence confocal
and bright-ﬁeld merged image. (df) TEM images of Hela cells (4  105
cells mL1) internalized with luciferaseluciferin Au-MSNs (50 μg mL1)
for 3 h. The images increase in magniﬁcation from left to right.
Figure 5. (a) Luminescence from Hela cells (4  105 cells mL1)
measured after 3 h of incubation with 50 μg mL1 luciferaseluciferin
Au-MSNs (black) or a solution containing free luciferase (1 mg mL1)
and luciferin (40 μM) (red) compared with untreated cells (blue). (b)
Observed luminescence of Hela cells (4  105 cells mL1) after
preincubation with luciferaseluciferin Au-MSNs (50 μg mL1) for 3 h;
1 mM DTT was added at t = 30 min.
18557 dx.doi.org/10.1021/ja2080168 |J. Am. Chem. Soc. 2011, 133, 18554–18557
Journal of the American Chemical Society COMMUNICATION
intracellular reducing environment. As shown in Figure 5b,
addition of 1 mM DTT after the decay of the initial intracellular
disulﬁde-reducing antioxidant triggered luminescence that after
10 min reached a peak signal 5-fold higher than the highest initial
luminescence and then gradually decayed, in accord with the in situ
controlled-release experiment shown Figure 3b. Therefore, this
system aﬀords the possibility of serving as not only a universal
enzymesubstrate carrier for intracellular controlled catalysis but
also a unique reporter for monitoring the intracellular redox poten-
tial for the study of drug delivery, cell viability, and tumor growth.
In conclusion, the present study has introduced a novel ap-
proach to intracellular codelivery of enzyme and substrate that
enables the system to be utilized in intracellular controlled catalysis.
Although we have demonstrated only the codelivery of luciferase
and luciferin in this study, the concept of delivering multiple
biogenic agents using such systems could also be extended to
other enzymatic reactions by exchanging the enzymesubstrate
pair. In addition, it has been recently observed thatMSNs are able
to undergo exocytosis and harvest intracellular biomolecules,36 and
thus, we envision that our system could not only conduct biocata-
lysis inside live cells but also sequester the product out of cells for a
variety of biotechnological applications.
The luciferaseluciferin Au-MSN system was designed to
allow imaging and quantiﬁcation of the intracellular catalysis for
system optimization but also aﬀords a unique route toward
monitoring tumor growth and metastasis by means of biolumi-
nescence and using intracellular ATP and GSH levels as indica-
tors. In comparison with traditional bioluminescence assays,
which generally employ gene engineering and multiple luciferin
injections, only one system needs to be delivered in this strategy.
Rapid readouts of the luminescence arising fromNP internalization
and the intracellular GSH-mediated luciferaseluciferin reaction
provide a unique platform for evaluating tumor development and a
convenient way of monitoring the response to treatments and
measuring the therapeutic eﬃcacy, which is of importance for me-
dical diagnosis and drug screening and development.
’ASSOCIATED CONTENT
bS Supporting Information. Experimental details and char-






†Deceased on May 4, 2010.
’ACKNOWLEDGMENT
This work is dedicated to thememory ofDr. Victor Shang-Yi Lin.
B.G.T., X.S., and Y.Z. thank the U.S. National Science Foundation
(CHE-0809521) and I.I.S. thanks the Ames Laboratory, U.S.
Department of Energy, Oﬃce of Basic Energy Sciences (Contract
DE-AC02-07CH11358) for support to complete this project.
’REFERENCES
(1) Zhao, Y.; Vivero-Escoto, J. L.; Slowing, I. I.; Trewyn, B. G.; Lin,
V. S.-Y. Expert Opin. Drug Delivery 2010, 7, 1013.
(2) Slowing, I. I.; Trewyn, B. G.; Lin, V. S.-Y. J. Am. Chem. Soc. 2007,
129, 8845.
(3) Bale, S. S.; Kwon, S. J.; Shah, D. A.; Banerjee, A.; Dordick, J. S.;
Kane, R. S. ACS Nano 2010, 4, 1493.
(4) Ghosh, P.; Yang, X.; Arvizo, R.; Zhu, Z.-J.; Agasti, S. S.; Mo, Z.;
Rotello, V. M. J. Am. Chem. Soc. 2010, 132, 2642.
(5) Bale, S. S.; Kwon, S. J.; Shah, D. A.; Kane, R. S.; Dordick, J. S.
Biotechnol. Bioeng. 2010, 107, 1040.
(6) Ahmann, F. R.; Garewal, H. S.; Schifman, R.; Celniker, A.;
Rodney, S. In Vitro Cell. Dev. Biol. 1987, 23, 474.
(7) Meyer, A. J.; Brach, T.; Marty, L.; Kreye, S.; Rouhier, N.; Jacquot,
J.-P.; Hell, R. Plant J. 2007, 52, 973.
(8) Balendiran, G. K.; Dabur, R.; Fraser, D. Cell Biochem. Funct.
2004, 22, 343.
(9) Wu, G.; Fang, Y.-Z.; Yang, S.; Lupton, J. R.; Turner, N. D. J. Nutr.
2004, 134, 489.
(10) Zhao, Y.; Trewyn, B. G.; Slowing, I. I.; Lin, V. S.-Y. J. Am. Chem.
Soc. 2009, 131, 8398.
(11) Torney, F.; Trewyn, B. G.; Lin, V. S.-Y.; Wang, K. Nat.
Nanotechnol. 2007, 2, 295.
(12) Sweeney, T. J.; Mailander, V.; Tucker, A. A.; Olomu, A. B.;
Zhang, W.; Cao, Y.-A.; Negrin, R. S.; Contag, C. H. Proc. Natl. Acad. Sci.
U.S.A. 1999, 96, 12044.
(13) Jenkins, D. E.; Oei, Y.; Hornig, Y. S.; Yu, S.-F.; Dusich, J.;
Purchio, T.; Contag, P. R. Clin. Exp. Metastasis 2003, 20, 733.
(14) Liu, J. J.; Wang, W.; Dicker, D. T.; El-Deiry, W. S. Cancer Biol.
Ther. 2005, 4, 885.
(15) Chandran, S. S.; Williams, S. A.; Denmeade, S. R. Luminescence
2009, 24, 35.
(16) Shinde, R.; Perkins, J.; Contag, C. H. Biochemistry 2006,
45, 11103.
(17) Edinger, M.; Sweeney, T. J.; Tucker, A. A.; Olomu, A. B.;
Negrin, R. S.; Contag, C. H. Neoplasia 1999, 1, 303.
(18) Lundin, A.; Rickardsson, A.; Thore, A. Anal. Biochem. 1976,
75, 611.
(19) DeLuca, M.; McElroy, W. D. Biochemistry 1974, 13, 921.
(20) Berger, F.; Paulmurugan, R.; Bhaumik, S.; Gambhir Sanjiv, S.
Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 2275.
(21) Matsumura, Y.; Maeda, H. Cancer Res. 1986, 46, 6387.
(22) Hong, R.; Fischer, N. O.; Verma, A.; Goodman, C. M.; Emrick,
T.; Rotello, V. M. J. Am. Chem. Soc. 2004, 126, 739.
(23) Lai, C.-Y.; Trewyn, B. G.; Jeftinija, D. M.; Jeftinija, K.; Xu, S.;
Jeftinija, S.; Lin, V. S.-Y. J. Am. Chem. Soc. 2003, 125, 4451.
(24) Giri, S.; Trewyn, B. G.; Stellmaker, M. P.; Lin, V. S.-Y. Angew.
Chem., Int. Ed. 2005, 44, 5038.
(25) Brust, M.; Walker, M.; Bethell, D.; Schiﬀrin, D. J.; Whyman, R.
J. Chem. Soc., Chem. Commun. 1994, 801.
(26) Leach, F. R.; Webster, J. J. Methods Enzymol. 1986, 133, 51.
(27) Lin, S.; Cohen, H. P. Anal. Biochem. 1968, 24, 531.
(28) Taluja, A.; Bae, Y. H. Pharm. Res. 2007, 24, 1517.
(29) Lomakina, G. Y.; Modestova, Y. A.; Ugarova, N. N. Vestn. Mosk.
Univ., Ser. 2: Khim. 2008, 49, 81.
(30) Hed, J.; Hallden, G.; Johansson, S. G.; Larsson, P. J. Immunol.
Methods 1987, 101, 119.
(31) Slowing, I.; Trewyn, B. G.; Lin, V. S.-Y. J. Am. Chem. Soc. 2006,
128, 14792.
(32) Arvizo, R.; Bhattacharya, R.; Mukherjee, P. Expert Opin. Drug
Delivery 2010, 7, 753.
(33) Gordon, J. L. Biochem. J. 1986, 233, 309.
(34) Pellegatti, P.; Raﬀaghello, L.; Bianchi, G.; Piccardi, F.; Pistoia,
V.; Di Virgilio, F. PLoS One 2008, 3, No. e2599.
(35) Bayele, H. K.; Ramaswamy, C.; Wilderspin, A. F.; Srai, K. S.;
Toth, I.; Florence, A. T. J. Pharm. Sci. 2006, 95, 1227.
(36) Slowing, I. I.; Vivero-Escoto, J. L.; Zhao, Y.; Kandel, K.;
Peeraphatdit, C.; Trewyn, B. G.; Lin, V. S.-Y. Small 2011, 7, 1526.
